Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy.
Department of Chemical and Pharmaceutical Sciences, University of Trieste, 34127 Trieste, Italy.
Int J Mol Sci. 2022 Apr 19;23(9):4504. doi: 10.3390/ijms23094504.
Amyotrophic lateral sclerosis (ALS) is a degenerating disease involving the motor neurons, which causes a progressive loss of movement ability, usually leading to death within 2 to 5 years from the diagnosis. Much effort has been put into research for an effective therapy for its eradication, but still, no cure is available. The only two drugs approved for this pathology, Riluzole and Edaravone, are onlyable to slow down the inevitable disease progression. As assessed in the literature, drug targets such as protein kinases have already been extensively examined as potential drug targets for ALS, with some molecules already in clinical trials. Here, we focus on the involvement of another very important and studied class of biological entities, G protein-coupled receptors (GPCRs), in the onset and progression of ALS. This workaimsto give an overview of what has been already discovered on the topic, providing useful information and insights that can be used by scientists all around the world who are putting efforts into the fight against this very important neurodegenerating disease.
肌萎缩侧索硬化症（ALS）是一种涉及运动神经元的退行性疾病，会导致运动能力逐渐丧失，通常在诊断后 2 至 5 年内导致死亡。为了寻找有效的治疗方法以彻底治愈这种疾病，人们付出了巨大的努力，但目前仍然没有治愈方法。目前仅批准了两种用于治疗这种疾病的药物，即利鲁唑和依达拉奉，这两种药物只能减缓疾病的必然进展。正如文献中所评估的，蛋白激酶等药物靶点已被广泛研究为 ALS 的潜在药物靶点，一些分子已经在临床试验中。在这里，我们重点关注另一种非常重要且经过广泛研究的生物实体，即 G 蛋白偶联受体（GPCRs），在 ALS 的发病和进展中的作用。这项工作旨在概述该领域已经发现的内容，提供有用的信息和见解，以供全世界致力于对抗这种非常重要的神经退行性疾病的科学家们参考。
Zotero 插件
